{"filing":{"accession_number":"0001193125-26-271863","cik":"0002027329","ticker":"OPTHF","company_name":"Optimi Health Corp.","form":"6-K","filing_date":"2026-06-16","report_date":null,"primary_document":"d157521d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2027329/000119312526271863/d157521d6k.htm"},"events":[{"id":12327,"run_id":10895,"accession_number":"0001193125-26-271863","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Optimi Health announced completion of production and commercial availability of two new standardized microdose psilocybin finished drug products (1mg and 2mg formulations). This represents a material operational and product-development milestone for a commercial-stage pharmaceutical manufacturer—the launch of new regulated drug products extends the company's product portfolio and supports its clinical research and patient-access business model. While not a discrete M\u0026A, financing, or governance event, the announcement of new finished drug products available for clinical research and commercial supply is a material operational development that would affect a reasonable investor's assessment of the company's commercial progress and revenue potential.","company_name":"Optimi Health Corp.","ticker":"OPTHF","filing_date":"2026-06-16","form":"6-K","submitted_at":null,"items":[{"id":9150,"accession_number":"0001193125-26-271863","item_number":"EX-99.1","item_title":"d157521dex991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Optimi Health announced completion of production and commercial availability of two new standardized microdose psilocybin finished drug products (1mg and 2mg formulations). This represents a material operational and product-development milestone for a commercial-stage pharmaceutical manufacturer—the launch of new regulated drug products extends the company's product portfolio and supports its clinical research and patient-access business model. While not a discrete M\u0026A, financing, or governance event, the announcement of new finished drug products available for clinical research and commercial supply is a material operational development that would affect a reasonable investor's assessment of the company's commercial progress and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:38:06.864544+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9150,"accession_number":"0001193125-26-271863","item_number":"EX-99.1","item_title":"d157521dex991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Optimi Health announced completion of production and commercial availability of two new standardized microdose psilocybin finished drug products (1mg and 2mg formulations). This represents a material operational and product-development milestone for a commercial-stage pharmaceutical manufacturer—the launch of new regulated drug products extends the company's product portfolio and supports its clinical research and patient-access business model. While not a discrete M\u0026A, financing, or governance event, the announcement of new finished drug products available for clinical research and commercial supply is a material operational development that would affect a reasonable investor's assessment of the company's commercial progress and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:38:06.864544+00:00","company_name":"Optimi Health Corp.","ticker":"OPTHF","filing_date":"2026-06-16"}]}